Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 4:20 pm Purchase |
2021-12-31 | 13G | Xeris Biopharma Holdings, Inc. XERS |
James E. Flynn | 5,882,353 4.500% |
5,882,353 (New Position) |
Filing History |
| 2022-02-11 4:19 pm Purchase |
2021-12-31 | 13G | Surrozen, Inc. SRZN |
James E. Flynn | 11,111 0.470% |
11,111 (New Position) |
Filing History |
| 2022-02-11 4:19 pm Sale |
2021-12-31 | 13G | Beyond Air, Inc. XAIR |
James E. Flynn | 833,334 3.030% |
-23,529 (-2.75%) |
Filing History |
| 2022-02-11 4:18 pm Sale |
2021-12-31 | 13G | Wave Life Sciences Ltd. WVE |
James E. Flynn | 552,690 0.940% |
-3,357,740 (-85.87%) |
Filing History |
| 2022-02-11 4:17 pm Sale |
2021-12-31 | 13G | Meridian Bioscience, Inc. VIVO |
James E. Flynn | 1,125,083 2.590% |
-1,035,917 (-47.94%) |
Filing History |
| 2022-02-11 4:17 pm Sale |
2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
James E. Flynn | 1,867,467 3.710% |
-853,736 (-31.37%) |
Filing History |
| 2022-02-11 4:16 pm Purchase |
2021-12-31 | 13G | GeneDx Holdings Corp. WGS |
James E. Flynn | 423,237 5.790% |
3,586 (+0.85%) |
Filing History |
| 2022-02-11 4:15 pm Sale |
2021-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
James E. Flynn | 2,345,959 9.280% |
-36,074 (-1.51%) |
Filing History |
| 2022-02-11 4:14 pm Sale |
2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
James E. Flynn | 2,154,061 7.840% |
-133,883 (-5.85%) |
Filing History |
| 2022-02-11 4:14 pm Purchase |
2021-12-31 | 13G | Nuvalent, Inc. NUVL |
James E. Flynn | 24,776,278 45.140% |
24,776,278 (New Position) |
Filing History |
| 2022-02-11 4:13 pm Purchase |
2021-12-31 | 13G | Profound Medical Corp. PROF |
James E. Flynn | 1,713,797 8.250% |
673,376 (+64.72%) |
Filing History |
| 2022-02-11 4:13 pm Purchase |
2021-12-31 | 13G | Ignyte Acquisition Corp. IGNY |
James E. Flynn | 725,000 9.950% |
725,000 (New Position) |
Filing History |
| 2022-02-11 4:12 pm Unchanged |
2021-12-31 | 13G | Orchard Therapeutics plc ORTX |
James E. Flynn | 694,942 5.540% |
0 (Unchanged) |
Filing History |
| 2022-02-11 4:12 pm Sale |
2021-12-31 | 13G | Apria, Inc. APR |
James E. Flynn | 1,655,795 4.670% |
-775,622 (-31.90%) |
Filing History |
| 2022-02-11 4:12 pm Purchase |
2021-12-31 | 13G | Organogenesis Holdings Inc. ORGO |
James E. Flynn | 8,456,876 6.570% |
762,513 (+9.91%) |
Filing History |
| 2022-02-11 4:11 pm Sale |
2021-12-31 | 13G | BioDelivery Sciences International, Inc. BDSI |
James E. Flynn | 29,204 0.030% |
-9,500,796 (-99.69%) |
Filing History |
| 2022-02-11 4:11 pm Sale |
2021-12-31 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
James E. Flynn | 3,282,912 10.720% |
-166,000 (-4.81%) |
Filing History |
| 2022-02-11 4:11 pm Sale |
2021-12-31 | 13G | Werewolf Therapeutics, Inc. HOWL |
James E. Flynn | 958,125 3.470% |
-1,594,662 (-62.47%) |
Filing History |
| 2022-02-11 4:10 pm Purchase |
2021-12-31 | 13G | Pulmonx Corporation LUNG |
James E. Flynn | 2,366,867 6.420% |
415,980 (+21.32%) |
Filing History |
| 2022-02-11 4:10 pm Sale |
2021-12-31 | 13G | IVERIC bio, Inc. ISEE |
James E. Flynn | 4,761,138 4.150% |
-1,006,271 (-17.45%) |
Filing History |